Allied Market Research
image  Direct : +1 (617) 674-4143 | Toll Free : +1 (855) 711-1555


Report Image
Global Companion Diagnostic Technologies Market (Indication and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020
Published: Jun-2014    |    Formats: PDF & Excel   |   Author(s):Alisha Menezes   |   Code: DI 14135
  • Report
    Overview
  • Table of
    Contents
  • Research
    Methodology
  • Analyst's
    Review
  • Sample

Pages 107
Tables 38

Companion diagnostics are in-vitro diagnostics that provide information about therapeutic responses of patients for a specific treatment. Companion diagnostics market is still nascent, and it is projected to reach $3.5 billion by 2020 from a base value of $1.1 billion in 2013, growing at a CAGR of 20% during 2014 to 2020. The global companion diagnostic market is segmented based on indication, technology and geography (North America, Europe, Asia Pacific and LAMEA). Geographically, LAMEA is the fastest growing region. The key drivers for this market are the increase in the discovery of biomarkers and co-development of drug and corresponding diagnostic. However, cost associated with developing drugs could impede the growth of this market. Opportunities for this market lie in developing companion diagnostics for various central nervous system conditions and hereditary conditions.

Companion Diagnostics Indication Market Analysis

Companion diagnostics is segmented on the basis of its use for indications such as oncology, cardiovascular conditions, central nervous system indications, inflammation and virology. Oncology is the highest revenue generating segment, as majority of the companion diagnostics have been developed for detection of various cancer biomarkers. The key driver for this market is an increase in research and development of targeted drugs, which require a corresponding companion diagnostic.

Companion Diagnostics Technology Market Analysis

Companion diagnostics technology market is segmented into Immunohistochemistry and Molecular diagnostics. Molecular diagnostics would be the fastest growing and highest revenue generator, mainly due to the use of techniques such as real time PCR, In Situ Hybridization and next generation sequencing. Other factors contributing to the growth is technological advancements in molecular diagnostics, which has resulted in increased accuracy and precision and also reduced cost of testing using these methods.

Companion Diagnostics Geography Market Analysis

Companion Diagnostics market has been segmented geographically into North America, Europe, Asia Pacific and LAMEA. North America has the major market share of 43.97% followed by Europe, which accounted for about 38% of the overall CD market in 2013. North America and Europe together accounted for over 82% in the global CD market in 2013 and they would continue to be the major markets through 2020. This is mainly due to the increasing incidence of cancer and other diseases and higher health care awareness in these regions. 

Competitive Analysis

A study of some of the key players has showed that majority of the companies in this market are focusing on collaborations with drug companies. Companion diagnostics is a emerging market and companies are collaborating with drug companies to develop companion diagnostics for their pipeline drugs, which are in developing phase. Approvals for companion diagnostics are the second most popular strategy. Companies profiled in this report include Dako (Agilent Technologies), Qiagen, Roche, Abbott Laboratories, Inc., Ventana Medical Systems, bioMerieux, Myriad Genetics, Inc., Resonance Health Ltd., Leica Microsystems, and Life Technologies.

High Level Analysis

The report is focusing on the trends in technology and diagnosis of various indications, which are driving the growth of the companion diagnostics market. Analysis of the market based on porters five force model shows that the bargaining power of the suppliers is high as the products produced are highly differentiated. The threat of new entrants is low as significant research and development is required for developing diagnostic tests. Apart from the R&D requirements, the investment required is also high. These factors make it difficult for new companies to enter the market. The threat of substitutes is low in this market as companion diagnostics are developed for specific biomarkers and the products are highly differentiated. Competition in this market is moderate as the market is still emerging and there are a few companies in the market. Government regulations are favoring use of companion diagnostics for determining a particular treatment. Companies are focusing on collaborations with pharmaceutical companies as a key strategy to gain competitive advantage. 

Reason for doing the study 

Companion diagnostics are an important aspect of the personalized treatment approach and are essential for predicting the therapeutic response to a particular drug. With increasing awareness among the population and rising incidences of cancer, companion diagnostics would become an essential factor for targeted therapeutic approach. More and more companies are developing targeted therapeutics products and companion diagnostics is an integral part of their strategy.

http://www.alliedmarketresearch.com

KEY BENEFITS

  • In-depth analysis of the companion diagnostic market by technology and indications give a clear idea of the scope of this market
  • Analysis of the market by geography would help in making region specific plans
  • Estimations for period of 2013 to 2020 have been given, taking into consideration the current market scenario and future trends, which would give a clearer picture of the potential of the market
  • Porter’s five force model and SWOT analysis would help in a deeper understanding of the market and help in making strategic decisions
  • Top factors impacting the market would help in making decisions for business development 

KEY DELIVERABLES

MARKET BY INDICATIONS

  • Oncology 
  • Cardiovascular 
  • Central Nervous System 
  • Auto immune & Inflammation 
  • Virology
  • Others

MARKET BY TECHNOLOGY 

  • Immunohistochemistry
  • Molecular diagnostics
    • In situ Hybridization
      • FISH
      • CISH
    • Real time PCR
    • Gene Sequencing 

MARKET BY GEOGRAPHY 

  • North America
  • Europe
  • Asia Pacific 
  • LAMEA

CHAPTER 1. INTRODUCTION

1.1 Report description
1.2 Key market segments
1.3 Research methodology

1.3.1 Secondary research
1.3.2 Primary research
1.3.3 Analyst tools and models

CHAPTER 2. EXECUTIVE SUMMARY

CHAPTER 3. MARKET OVERVIEW 

3.1 Market Definition and Scope
3.2 Companion Diagnostics for Metabolic Diseases
3.3 Novel trends and technologies in companion diagnostics assay development
3.4 Companion diagnostics as a new trend in personalized medicine
3.5 Biomarkers market as basis for the companion diagnostics industry
3.6 Key Findings

3.6.1 Top Factors Impacting The Companion Diagnostic Market
3.6.2 Top Winning Strategies

3.7 Porter’s five forces analysis

3.7.1 High switching cost leads to higher bargaining power of suppliers
3.7.2 Highly differentiated products leads to lower bargaining power of buyers
3.7.3 Specificity of diagnostics lowers the threat of substitutes
3.7.4 Higher capital investment leads to lesser threat of entrants
3.7.5 Few competitors leads to low competition among players

3.8 Government Regulations

3.8.1 FDA regulations
3.8.2 Europe
3.8.3 Japan
3.8.4 China

3.9 Value Chain Analysis
3.10 Case Study
3.11 Drivers

3.11.1 Increased popularity of Personalized medicine
3.11.2 Increasing cases of adverse drug reactions(ADRs)
3.11.3 Increase in the Discovery of Biomarkers as drug targets.
3.11.4 Rising success of co-development drugs speedily approved by the FDA
3.11.5 Technological advancements
3.11.6 Rising incidences of diseases

3.12 Restraints

3.12.1 High Cost in research and development of drugs

3.12.1.1 Economic and scientific obstacles

3.12.2 Opportunities

3.12.2.1 Opportunities in treatment of neurodegenerative diseases
3.12.2.2 Companion diagnostics for hereditary mutations

CHAPTER 4. GLOBAL COMPANION DIAGNOSTIC MARKET BY INDICATIONS

4.1 Oncology

4.1.1 Companion diagnostics oncology market by geography,
4.1.2 Breast Cancer

4.1.2.1 companion diagnostics breast cancer market by geography

4.1.3 Lung Cancer

4.1.3.1 companion diagnostics lung cancer market by geography

4.1.4 Colorectal Cancer

4.1.4.1 companion diagnostics Colorectal Cancer market by geography

4.1.5 Gastric cancer

 4.1.5.1 companion diagnostics Gastric Cancer market by geography

4.1.6 Melanomas

4.1.6.1 companion diagnostics Melanoma market by geography

4.2 Inflammation and Autoimmune diseases

4.2.1 Companion diagnostics inflammation market by geography

4.3 Companion diagnostics in cardiovascular diseases

4.3.1 Companion diagnostics tests for warfarin
4.3.2 Companion diagnostics cardiovascular market by geography

4.4 Companion diagnostics in CNS disorders

4.4.1 Companion diagnostics CNS market by geography

4.5 Companion diagnostics tests in virology diseases

4.5.1 Companion diagnostics virology market by geography

4.6 Others

4.6.1 Companion diagnostics others market by geography

CHAPTER 5. GLOBAL COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY

5.1 Companion diagnostics technology market by geography
5.2 Immunohistochemistry

5.2.1 Companion diagnostics Immmunohistochemistry market by geography

5.3 Molecular Diagnostics

5.3.1 Companion diagnostics molecular diagnostics market by types
5.3.2 Companion diagnostics Molecular Diagnostics market by geography
5.3.3 In-situ Hybridization    

5.3.3.1 Fluorescent In-situ Hybridization(FISH)
5.3.3.2 CISH (Chromogenic In-Situ Hybridization)
5.3.3.3 Companion diagnostics In situ Hybridization market by geography

5.3.4 Real Time PCR

5.3.4.1 Companion diagnostics RT PCR market by geography

5.3.5 Gene Sequencing

5.3.5.1 Companion diagnostics Sequencing market by geography

5.3.6 Others

5.3.6.1 Others molecular companion diagnostics market by geography

CHAPTER 6. GLOBAL COMPANION DIAGNOSTICS BY GEOGRAPHY

6.1 North America

6.1.1 Companion diagnostics North America market by indication

6.2 Europe

6.2.1 Companion diagnostics Europe market by indication

6.3 Asia Pacific

6.3.1 Companion diagnostics Asia Pacific market by indication

6.4 RoW

6.4.1 Companion diagnostics RoW market by indication

CHAPTER 7. COMPANY PROFILES

7.1 Qiagen

7.1.1 Company Overview:
7.1.2 Company Snapshot
7.1.3 Business Performance
7.1.4 Strategy move and development

7.1.4.1    Principal strategies Collaborations
7.1.4.2    Secondary Strategies Approval

7.1.5 SWOT Analysis of Qiagen

7.2 Dako (Agilent Technologies)

7.2.1 Company Overview
7.2.2 Company Snapshot
7.2.3 Business Performance
7.2.4 Strategic Moves and Development

7.2.4.1  Principal strategies Collaboration
7.2.4.2  Secondary Strategies Approval

7.2.5 SWOT Analysis of Dako

7.3 Roche

7.3.1 Company overview
7.3.2 Company Snapshot
7.3.3 Business Performance
7.3.4 Strategies move and development
7.3.5 SWOT analysis of Roche

7.4 Abbott Laboratories, Inc.

7.4.1 Company Overview
7.4.2 Company Snapshot
7.4.3 Business Performance
7.4.4 Principal Strategies Collaboration
7.4.5 SWOT Analysis of Abbot

7.5 BioMerieux 

7.5.1 Company Overview
7.5.2 Company snapshot:
7.5.3 Business Performance
7.5.4 Strategies and development Approval
7.5.5 SWOT Analysis of BioMerieux, 

7.6 Ventana Medical Systems

7.6.1 Company Profile
7.6.2 Company Snapshot
7.6.3 Business Performance
7.6.4 Strategies and development  
7.6.5 SWOT Analysis of Ventana

7.7 Myriad Genetics, Inc.

7.7.1 Company Overview
7.7.2 Company snapshot
7.7.3 Business Performance
7.7.4 Strategies  and  development
7.7.5 SWOT Analysis of Myraid

7.8 Resonance Health Ltd

7.8.1 Company Overview
7.8.2 Company Snapshot
7.8.3 Strategies move and development
7.8.4 SWOT Analysis of Ferriscan

7.9 Leica Microsystems

7.9.1 Company overview
7.9.2 Company Snapshot
7.9.3 Strategies move and Development
7.9.4 SWOT Analysis of Leica Microsystems

7.10 Life Technologies

7.10.1 Company Overview
7.10.2 Company Snapshot
7.10.3 Business performance
7.10.4 Strategies move and Development
7.10.5 SWOT Analysis of Life Technologies

 

LIST OF TABLES

TABLE 1    GLOBAL COMPANION DIAGNOSTICS MARKET BY INDICATION, 2013-2020 ($MILLION)
TABLE 2    COMPANION DIAGNOSTICS INDICATION MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 3    GLOBAL COMPANION DIAGNOSTICS MARKET BY ONCOLOGY, 2013-2020, ($MILLION)
TABLE 4    COMPANION DIAGNOSTICS ONCOLOGY MARKET BY GEOGRAPHY, 2013-2020, ($MILLION)
TABLE 5    COMPANION DIAGNOSTICS BREAST CANCER MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 6    COMPANION DIAGNOSTICS LUNG CANCER MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 7    COMPANION DIAGNOSTICS COLORECTAL CANCER MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 8    COMPANION DIAGNOSTICS GASTRIC CANCER MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 9    COMPANION DIAGNOSTICS MELANOMA MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 10 COMPANION DIAGNOSTICS INFLAMMATION MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 11 COMPANION DIAGNOSTICS CARDIOVASCULAR MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 12 COMPANION DIAGNOSTICS CNS MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 13 COMPANION DIAGNOSTICS VIROLOGY MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 14 COMPANION DIAGNOSTICS OTHERS MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 15 COMPANION DIAGNOSTICS TECHNOLOGY MARKET BY TECHNOLOGY 2013-2020 ($MILLION)
TABLE 16 COMPANION DIAGNOSTICS TECHNOLOGY MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 17 COMPANION DIAGNOSTICS IMMMUNOHISTOCHEMISTRY MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 18 COMPANION DIAGNOSTICS MOLECULAR DIAGNOSTICS MARKET BY TYPES 2013-2020 ($MILLION)
TABLE 19 COMPANION DIAGNOSTICS MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 20 COMPANION DIAGNOSTICS IN SITU HYBRIDIZATION MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 21 COMPANION DIAGNOSTICS RT PCR MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 22 COMPANION DIAGNOSTICS SEQUENCING MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 23 OTHERS MOLECULAR COMPANION DIAGNOSTICS MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 24 COMPANION DIAGNOSTICS OTHERS MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 25 COMPANION DIAGNOSTICS NORTH AMERICA MARKET, 2013-2020 ($MILLION)
TABLE 26 COMPANION DIAGNOSTICS EUROPE MARKET, 2013-2020 ($MILLION)
TABLE 27 COMPANION DIAGNOSTICS ASIA-PACIFIC MARKET, 2013-2020 ($MILLION)
TABLE 28 COMPANION DIAGNOSTICS ROW MARKET, 2013-2020 ($MILLION)
TABLE 29 QIAGEN SNAPSHOT
TABLE 30 DAKO COMPANY SNAPSHOT
TABLE 31 ROCHE COMPANY SNAPSHOT
TABLE 32 ABBOTT COMPANY SNAPSHOT
TABLE 33 BIOMERIEUX COMPANY SNAPSHOT
TABLE 34 VENTANA COMPANY SNAPSHOT
TABLE 35 MYRIAD COMPANY SNAPSHOT
TABLE 36 RESONANCE COMPANY SNAPSHOT
TABLE 37 LEICA COMPANY SNAPSHOT
TABLE 38 LIFE TECHNOLOGIES COMPANY SNAPSHOT

 

LIST OF FIGURES

FIG.1 COMPANION DIAGNOSTICS AS A NEW TREND IN PERSONALIZED MEDICINE
FIG.2 EFFECTIVENESS OF COMPANION DIAGNOSTICS IN LUNG CANCER PATIENTS
FIG.3 LIST BIOMARKERS AND THE COMPANION DIAGNOSTICS FOR VARIOUS DISEASES
FIG.4 TOP FACTORS IMPACTING THE COMPANION DIAGNOSTIC MARKET
FIG.5 TOP WINNING STRATEGIES
FIG.6 VALUE CHAIN ANALYSIS
FIG.7 FINANCIAL REVENUES BY BUSINESS UNITS (2013)
FIG.8 FINANCIAL REVENUES BY GEOGRAPHY(2013)
FIG.9 SWOT ANALYSIS OF QIAGEN
FIG.10 FINANCIAL REVENUE OF DAKO, BY SEGMENT (2012)
FIG.11 SWOT ANALYSIS OF DAKO
FIG.12 FINANCIAL REVENUE OF DAKO, BY SEGMENT
FIG.13 FINANCIAL REVENUE OF DAKO, BY GEOGRAPHY
FIG.14 SWOT ANALYSIS OF ROCHE
FIG.15 REVENUE BY BUSINESS SEGMENTS
FIG.16 REVENUE BY GEOGRAPHY
FIG.17 SWOT ANALYSIS OF ABBOTT
FIG.18 FINANCIAL REVENUES BY GEOGRAPHY
FIG.19 FINANCIAL REVENUES BY TECHNOLOGY
FIG.20 SWOT ANALYSIS OF BIOMERIEUX
FIG.21 SWOT ANALYSIS OF VENTANA
FIG.22 REVENUE BY DIAGNOSTIC TYPE
FIG.23 SWOT ANALYSIS OF MYRAID
FIG.24 SWOT ANALYSIS OF FERRISCAN
FIG.25 SWOT ANALYSIS OF LEICA MICROSYSTEMS
FIG.26 REVENUE BY END MARKETS
FIG.27 SWOT ANALYSIS OF LIFE TECHNOLOGIES

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

Companion diagnostics are used to identify patients most likely to benefit from treatment with a particular drug. This market is an emerging market with very few approved products currently available. The market is dependent on research and development of new drugs and discovery of biomarkers. Increase in research and development of targeted therapies and discovery of new biomarkers for various conditions is driving growth of this market. The challenge to this market is co-ordination of co-development of drug and diagnostic. The global companion diagnostics market is segmented into three categories viz. cancer biomarkers, technology and geography.

This market research report is an effort to provide the clear picture of the state of the market and sub markets over the next seven years. The report provides micro level analysis of the factors affecting the market, key market trends and industry drives and challenges for the better understanding of the market structure. The presentation of the market dynamics, competitive scenario and developments will enable marketers to aptly design their growth strategies and have competitive edge. Moreover, assessment of the top investment pockets and winning strategies will help in channelizing their investments in the right directions to garner better proceeds.

SIMILAR MARKET STUDIES

Published Reports

Regenerative medicines have the unique ability to repair, replace and regenerate tissues and organs, affected due to some injury, disease or due to natural aging process. These medicines are capable of restoring the functionality of cells and tissues. These medicines find applicability in wide range of degenerative disorders including dermatology, neurodegenerative diseases, cardiovascular and orthopedic applications. Researchers are engaged in developing technologies based on biologics, genes, somatic as well as stem cells.
30 Jun 2014 | Price: $4515(SU) | View Details >>

DNA diagnostics is a cutting edge method which is set to revolutionize the field of medical diagnostics. This technique enables medical professionals to identify various diseases, such as cancer, infectious diseases, and myogenic disorders, and to determine the appropriate treatment for the same. It is also used for clinical diagnostic confirmation and in prenatal diagnostics.
27 Aug 2014 | Price: $4515(SU) | View Details >>

Synthetic biology is a novel field that finds its origin at the intersection of biology and engineering. It involves designing and construction of biological systems or devices that can be applied in varied domains to get specified results. Its a multidisciplinary effort made by scientists to understand the functioning of biological organisms, cells & genes and implementation of artificial genetic processes to give specific characteristics to an organism. It can even be used to develop a completely new biological system. Global synthetic biology market was valued at $3.0 billion in 2013 and it is estimated to reach $38.7 billion by 2020, growing at a CAGR of 44.2% during the forecast period.
27 May 2014 | Price: $4515(SU) | View Details >>

The bioinformatics market is expected to grow to $12.86 billion by 2020 with a CAGR of 21.2% during 2014-2020. Bioinformatics is an interdisciplinary field that is used in the development and storage of data, thus helping in the analysis, organization and retrieval of the biological data. Bioinformatics has various applications and thus forms part of almost all the fields in biology. Bioinformatics form a part of agriculture, animal breeding, molecular medicine, preventive medicine, etc. The major factors driving the bioinformatics market is the need for integrated data, rising demand for drug development and discovery, the increasing focus in genomics & proteomics and the favorable government initiatives.
28 May 2014 | Price: $4515(SU) | View Details >>

Umbilical cord blood stem cells are potential stem cells that can convert into any type of -determined cells. Global stem cell market is dominating the healthcare industry with its reliable and cost effective method of treatment with fewer side effects. Current market for cord blood therapeutics accounts for $6.5 billion, which is expected to grow at 33.4% CAGR from 2013-2020. Other segments of this market include - Adult stem cell and embryonic stem cells. Government authorities are supporting the research and clinical trials of cord blood stem cell, which is currently increasing the interest of healthcare companies to invest in research and commercialization of cord blood stem cell therapies.
21 Jan 2014 | Price: $4515(SU) | View Details >>

Upcoming Reports

Veterinary diagnostics are noninvasive methods used to identify and examine the causes of diseases in animals. Various new technologies from human diagnostics segments are being adapted for the veterinary domain. This trend is expected to continue in the future, thereby contributing to the growth of this market.
Price: $4515 | Pre Book Price: $4515 | View Details >>

The label free detection method is used for detecting biomolecules and their interactions. This method has emerged as an attractive research and development tool in the pharmaceutical and biotech industry.
Price: $4515 | Pre Book Price: $4515 | View Details >>

DNA sequencing is a process used to determine the order of nucleotides within DNA molecules. Prenatal DNA sequencing is the method of sequencing the DNA isolated from pregnant women’s blood to reveal the full genetic code of a fetus. Prenatal DNA sequencing is used to sequence the whole genome of unborn baby that effectively detects the diseases
Price: $4515 | Pre Book Price: $4515 | View Details >>

Identification documents and PIN are traditional methods used to verify the identity of a human being. However, an increasing number of cases of security threats, illegal transactions at ATMs, unauthorised immigration and unauthorised infiltration across borders are factors which have resulted in the evolution of new generation biometrics methods. New generation biometrics refers to technologies that are used to verify the identity of individuals through biological characteristics such as facial expression, voice, palm, fingerprints, signature, iris, vein and DNA.
Price: $4515 | Pre Book Price: $4515 | View Details >>

Tissue engineering is the combination of biology medicine and engineering to create products that would improve or replace biological functions or organs. More than a decade ago, the industry introduced the first FDA approved tissue-engineering product, which was a skin substitute product. These products provide natural regeneration of tissues or cells, and hence are highly effective. The medical biotechnology industry was estimated to be $160 billion in 2012.The major drivers in this industry are chronic wound and orthopedic application segment.
Price: $4515 | Pre Book Price: $4515 | View Details >>
First time Buyer ?
Check offer and
discount on this report


Get Discount

NEED MORE INFORMATION?
Call
+1 617 674 4143


Purchase Enquiry

PURCHASE OPTIONS

Single User
By obtaining a Single User License, you and your organization concur that only an individual uses this report either electronically or online. The right to use or stockpiling of the report should be confined only to one authorized computer. User will have authorization to print one duplicate of the report for individual use, yet may not be replicated for circulation. Additional copies for this report may also be order at discounted price for use by addition readers/users.
$4515

Multi User 
Multi-User license permits you to access the report from eight authorized computers. It does not permit you to display it on your company website and permits you to only print 5 copies of the report that shall not be reproduced for circulation.
$7515

Corporate  
With corporate use license, the complete or part of the content of the report can be shared or made available to other persons, other divisions and subsidiaries of same company. However, reproduction or redistribution of the report in is prohibited without the prior permission of Allied Market Research. The publisher will, in turn, regard the privacy of the purchaser and will keep it confidential. Upon buying single or multi-user license, buyer must provide the names and email ids of the authorized users of this report.
$10515


Not Interested in buying complete report?
To check the cost of chapters
WHY ALLIED MARKET RESEARCH?
INFALLIBLE METHODOLOGY
To ensure high level data integrity, accurate analysis and impeccable forecasts
ANALYST SUPPORT
For complete satisfaction
CUSTOMIZATION
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET
Targeted market view to eliminate redundant information to provide valued information and save time of the reader







Top